Search

Displaying results 4741 - 4750 of 10000 in total
  1. Drug

    Goflikicept

    go.drugbank.com/drugs/DB16396
    Investigational

    Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe

  2. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  3. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

  4. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  5. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen. … Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject.

  6. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. It is developed for the tr...

  7. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  8. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  9. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  10. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]